Skip to main content
padlock icon - secure page this page is secure

Dihydrofolate Reductase Gene Variations in Susceptibility to Disease and Treatment Outcomes

Buy Article:

$68.00 + tax (Refund Policy)

Dihydrofolate reductase (DHFR) catalyzes the reduction of dihydrofolate to tetrahydrofolate (THF). THF is needed for the action of folate-dependent enzymes and is thus essential for DNA synthesis and methylation. The importance of this reaction is demonstrated by the effectiveness of antifolate medications used to treat cancer by inhibiting DHFR, thereby depleting THF and slowing DNA synthesis and cell proliferation. Due to the pivotal role that DHFR plays in folate metabolism and cancer treatment, changes in the level of DHFR expression can affect susceptibility to a variety of diseases dependent on folate status such as spina bifida and cancer. Likewise, variability in DHFR expression can affect sensitivity to anti-cancer drugs such as the folate antagonist methotrexate. Alterations in DHFR expression can be due to polymorphisms in the DHFR gene. Several variations have recently been described in DHFR, including promoter polymorphisms, the 19-bp deletion allele and variations in 3'UTR. These polymorphisms seem to be functional, affecting mRNA levels through various interesting mechanisms, including regulation through RNA interference. Several groups have assessed the association of these polymorphisms with folate levels, risk of cancer and spina bifida as well as the outcome of diseases treated with MTX. The latter may lead to different treatment schedules, improving treatment efficacy and/or allowing for a reduction in drug side effects. This review will summarize present knowledge regarding the predictive potential of DHFR polymorphisms in disease and treatment.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: (NTD); 5-methyl-THF; DHFR; DHFR polymorphisms; Gene; MTHFR; MTX; Neural tube defects; S-adenosylmethionine; dihydrofolate; dihydrofolate reductase; dihydrofolate reductase (DHFR); disease susceptibility; folate cycle; hMSH3; homocysteine remethylation; lymphoblastic leukemia; methotrexate; methotrexate (MTX); methylene tetrahydrofolate reductase; polymorphisms; spina bifida; tetrahydrofolate; therapeutic response

Document Type: Research Article

Publication date: December 1, 2010

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more